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Abstract
Background: Brain inflammation has been recognized as a complex phenomenon with numerous
related aspects. In addition to the very well-described neurodegenerative effect of inflammation,
several studies suggest that inflammatory signals exert a potentially positive influence on neural
stem cell proliferation, migration and differentiation. Tumor necrosis factor alpha (TNF-α) is one
of the best-characterized mediators of inflammation. To date, conclusions about the action of TNF
on neural stem or progenitor cells (NSCs, NPCs) have been conflicting. TNF seems to activate
NSC proliferation and to inhibit their differentiation into NPCs. The purpose of the present study
was to analyze the molecular signal transduction mechanisms induced by TNF and resulting in NSC
proliferation.
Results: Here we describe for the first time the TNF-mediated signal transduction cascade in
neural stem cells (NSCs) that results in increased proliferation. Moreover, we demonstrate IKK-
α/β-dependent proliferation and markedly up-regulated cyclin D1 expression after TNF treatment.
The significant increase in proliferation in TNF-treated cells was indicated by increased
neurosphere volume, increased bromodeoxyuridin (BrdU) incorporation and a higher total cell
number. Furthermore, TNF strongly activated nuclear factor-kappa B (NF-κB) as measured by
reporter gene assays and by an activity-specific antibody. Proliferation of control and TNF-treated
NSCs was strongly inhibited by expression of the NF-κB super-repressor IκB-AA1.
Pharmacological blockade of IκB ubiquitin ligase activity led to comparable decreases in NF-κB
activity and proliferation. In addition, IKK-β gene product knock-down via siRNA led to diminished
NF-κB activity, attenuated cyclin D1 expression and finally decreased proliferation. In contrast,
TGFβ-activated kinase 1 (TAK-1) is partially dispensable for TNF-mediated and endogenous
proliferation. Understanding stem cell proliferation is crucial for future regenerative and anti-tumor
medicine.
Conclusion: TNF-mediated activation of IKK-β resulted in activation of NF-κB and was followed
by up-regulation of the bona-fide target gene cyclin D1. Activation of the canonical NF-κB pathway
resulted in strongly increased proliferation of NSCs.
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During mammalian central nervous system (CNS) devel-
opment, multipotent precursor cells (stem cells) undergo
division, cell fate specification, and maturation in
response to extrinsic cues. These neural stem cells are char-
acterized by the ability to undergo cell division and to dif-
ferentiate into multiple cell types, e.g. neurons or glial
cells.
There are two major sources of adult neural stem cells
within the adult brain: the subgranular zone of the hip-
pocampus and the subventricular zone (SVZ) [1,2]. SVZ-
derived NSCs can be cultured as self-adherent cell clusters
called neurospheres [2]. Such 3D neurospheres can be
kept in culture for several passages without losing their
proliferation, migration and differentiation capabilities.
Until the 1990s, all studies of neural stem cell prolifera-
tion were limited to examining the proliferation of precur-
sors in embryonic tissue. Recently, several isolation and
culture protocols have been established that have enabled
proliferation to be studied in cultured adult neural stem
cells [3-6]. It is noteworthy that under normal conditions,
proliferation (division) is tightly controlled. Cytokine-
induced cell death and dysfunction play an important role
in the pathogenesis of a variety of disease conditions,
including brain inflammation. However, cytokine pro-
duction within the adult brain is strongly up-regulated by
inflammation. This response has been well described in
demyelinating diseases, e.g. multiple sclerosis, experi-
mental autoimmune encephalomyelitis, viral or bacterial
infection, trauma and ischemia [7]. Much of the inflam-
matory signal transduction can be considered as an innate
immune response triggered by tumor necrosis factor
(TNF), one of the crucial inflammation mediators [8,9].
As a model for brain inflammation, we initially investi-
gated the transcriptional profile of TNF-treated astrogli-
oma cells [10]. We demonstrated more than 800 TNF-
regulated genes. Macrophage Chemoattractant Protein 1
(MCP-1) was strongly up-regulated and secreted into the
medium.
It is well established that neural stem cells express various
chemokine receptors as a result of brain pathology (see
[11] and [12]). In addition to MCP-1, expression of stro-
mal derived factor 1 (SDF1), stem cell factor (SCF) and
vascular endothelial growth factor (VEGF) has been
reported. In subsequent experiments, we therefore tested
the possibility that MCP-1 induces NSC migration [13]
and found a significant effect.
In view of the very well-described TNF secretion during
inflammatory diseases and the very potent induction of
NSC migration by MCP-1, we hypothesized that in path-
ological situations these cells migrate from the SVZ to the
area of the lesion. This hypothesis accords with a model
proposed by Muller et al. [11]. According to this model,
neural stem cells are attracted by inflammation, reactive
astrocytosis and angiogenesis. Thus, NSCs are exposed
after migration to TNF at the area of inflammation.
In the present study, we analyzed the biological effect and
signal transduction pathway of TNF in NSCs in vitro. The
advantage of the in vitro approach is a biochemically
defined environment with minimal risk of unwanted
cross-activation by cytokines and/or unknown in vivo cell-
cell interactions.
Within the nervous system, TNF (a 17 kDa protein) binds
to TNF receptors (TNF-Rs) expressed on both glia and
neurons [14]. Expression of the TNF-α gene is subject to
auto-regulation via activated NF-κB [15]. Two different
receptors have been identified: p55 (TNF-RI) and p75
(TNF-RII). The p55 receptor plays the major role in NF-κB
activation [16]. Furthermore, it has been shown that the
IKK-α/β-complex is crucial for TNF-mediated NF-κB acti-
vation [17], and there is evidence that TGFβ activated
kinase-1 (TAK-1) is involved in the TNF-induced signaling
cascade [18].
Cyclin dependent kinase 4 and 6 (CDK4/6) signaling is
crucial in neural stem cell cycle regulation [19]. Moreover,
formation of a complex between CDK 4 and cyclin D1 is
necessary for NSC cell cycle progression by promoting
passage through the G1/S restriction point. In contrast,
Burgess et al. showed clearly that CDK4/cyclin D3 in
tumor cells is critical for G2/M progression and the fidel-
ity of mitosis [20]. Kaltschmidt et al. described cyclin D1-
dependent proliferation of HeLa cells, which was abro-
gated by over-expression of IκB [21]. Guttridge et al. were
the first to show that NF-κB controls proliferation through
transcriptional regulation of cyclin D1 in embryonic
fibroblasts [22].
In this study, we describe for the first time the TNF-medi-
ated signal cascade in adult neural stem cells. TNF treat-
ment leads to strong IKK-mediated NF-κB activation and
up-regulation of cyclin D1 expression, resulting in
increased proliferation. Taken together, these results show
that NF-κB has a crucial role in the proliferation of NSCs
induced by inflammation.
Results
Characterization of neural stem cells derived from the 
adult subventricular zone
The generation of neural stem/progenitor cells isolated
from the subventricular zone was studied using specific
stem-cell markers such as Nestin, Sox2, doublecortin and
Musashi (see Fig. 1A). Most of the NSCs were Nestin-
immunoreactive, a characteristic of neural stem cells, andPage 2 of 18
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factor SOX2 [23]. Furthermore, they expressed doublecor-
tin (DCX), a marker for newborn immature neurons that
is also detected in proliferating neural cells [24], and the
RNA-binding protein Musashi, which is essential for neu-
rosphere formation and proliferation [25]. The popula-
tion markers L1 and LeX, and the oligodendrocytic lineage
marker A2B5, were not expressed. Moreover, we detected
moderate expression of PSA-NCAM, a marker for migrat-
ing neuronal precursor cells. The differentiation markers
β-III-tubulin (for neurons) and GFAP (for glial cells) were
not expressed (data not shown). In order to analyze the
effect of TNF on the NSCs, we investigated the expression
of the specific TNF receptors I and II. Immunocytochemi-
Expression pattern of cultured, rat derived neurospheresFigure 1
Expression pattern of cultured, rat derived neurospheres. (A)Neurospheres were collected on glass slides by cytospin 
centrifugation, fixed and stained for Nestin, Sox2, DCX, Musashi, L1, LeX, PSA-NCAM and A2B5. DNA was stained using 
SYTOX (green). Most of the cells analyzed were positive for Nestin, Sox2, DCX, Musashi, Notch-1 (data not shown) and 
Notch-2 (data not shown) and negative for L1, LeX and the differentiation marker A2B5 for oligodendrocyte progenitors. 
Moreover, we detected moderate expression of PSA-NCAM, a marker for migrating neuronal precursor cells. Bar, 50 μm. (B) 
Neurospheres express both TNF-receptors. Neurospheres were collected, fixed and stained for TNFR-I and TNFR-II. Nuclei 
were stained with SYTOX (green). Note the high expression of both TNFR-I and II. (C) RT-PCR confirms expression of both 
TNF receptors. M: Marker, lane 1: TNFR-I, lane 2: TNFR-II. Lanes 3 and 4 are negative PCR controls without template.Page 3 of 18
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on the cell surfaces (Fig. 1B). The intracellular localization
of the TNF receptors (especially TNF-RII) is consistent
with the recent finding that TNF signalosomes are endo-
some-localized [26]. We also verified the expression of
TNF-RI and II by RT-PCR (see Fig. 1C).
TNF induces an increase in neurosphere volume
We used sub-cultured secondary neurospheres from pas-
sage 10 onwards. NSCs were treated for up to 4 days with
TNF in different concentrations (4 ng/ml and 10 ng/ml).
This resulted in a significant, dose-dependent increase in
volume of the 3D neurospheres (Fig. 2A, B). We then
asked whether the increased neurosphere volume results
from enhanced NSC proliferation.
Growth of neurospheres correlates with proliferation of 
NSCs
We analyzed stem cell proliferation by BrdU incorpora-
tion. This technique has been extensively used to measure
DNA replication during proliferation of mammalian cells.
Incorporation of BrdU was measured in control NSC cul-
tures and in cultures treated with 10 ng/ml TNF for 72 h
(Fig. 3A).
As expected, smaller spheres with lightly-labeled nuclei
were seen in control cultures owing to endogenous prolif-
eration. In contrast, TNF-treated neurospheres showed
strong BrdU incorporation, an indication of rapidly pro-
liferating cells. This might explain the marked increase in
neurosphere volume after 72 h of TNF treatment (see Fig.
4A). Thus, TNF significantly (p < 0.001) activated NSC
proliferation (Fig. 3B). BrdU incorporation was more than
6-fold higher in TNF-treated cells than in untreated con-
trols.
Cell counting was also used as an independent measure of
cell proliferation. TNF treatment significantly increased
the cell number (see Fig. 3C). This effect disappeared
when the cells were pre-incubated with IκB ubiquitin
ligase activity inhibitor PDTC. This is a first hint that NF-
κB is involved in TNF-mediated signaling (see also Fig. 9)
in adult NSCs.
TNF activates apoptosis only moderately in neural stem 
cells
Since one of the known physiological effects of TNF is the
induction of apoptosis, we analyzed the frequency of
apoptotic cells in TNF-treated NSCs. Cells were treated
with TNF for 3 days and analyzed for DNA fragmentation
using a TUNEL assay (Fig. 4). DNAse treatment as a posi-
tive control resulted in nearly 75% TUNEL-positive
nuclei. Label solution as a negative control gave no posi-
tive signal. In contrast, some apoptotic nuclei were
detected under control conditions. TNF treatment
increased the rate of apoptosis in NSCs only moderately
(Fig. 4). This result suggests that a major aspect of the
physiological action of TNF on NSCs might be the induc-
tion of proliferation.
TNF does not interfere with neural stem cell 
differentiation
The crucial property of stem cells is to differentiate into
more specialized cells, in our case into neuronal progeni-
tors, immature neurons or glial cells. We therefore inves-
tigated whether TNF might influence the capacity of NSCs
to differentiate into neurons. TNF-treated and untreated
cells were plated on laminin/poly-D-lysine coated culture
dishes for up to 3 days. This protocol is frequently used to
induce neuronal differentiation of NSCs. Cells positive for
β-III tubulin (a marker for immature neurons) with neu-
ron-like morphology were detected 3 days after plating
both with and without TNF treatment (Fig. 5A). The fre-
quency with which immature neurons differentiated from
the NSCs was not significantly affected (p > 0.05) by TNF
treatment (Fig. 5B). In addition, TNF treatment had no
effect on the capacity of the cells to differentiate into the
glial lineage, as demonstated by immunocytochemical
staining for glial fibrillary acidic protein (GFAP) four days
after plating in the presence of 10% fetal calf serum (FCS)
(Fig. 5C). This suggests that the action of TNF might be
specific only for the proliferation of NSCs; cell fate is not
affected.
TNF activates NF-κB in neural stem cells
One of the major signal transduction pathways activated
by TNF is the canonical NF-κB pathway. To investigate
TNF-mediated signal transduction, a highly efficient
transfection system was needed. We used a modified
Amaxa electroporation protocol (see Materials and Meth-
ods), which transfected up to 60–80% of the cells, as
shown by fluorescence microscopy and flow cytometry
(Fig. 6A). To evaluate the efficacy of transfection, we used
a commercially available expression vector for green fluo-
rescent protein (pmaxGFP, Amaxa, Köln, Germany).
In view of the well-described activation of NF-κB by TNF
in other systems such as various tumor cell lines, we trans-
fected NSCs with κB-luc reporter vector and Renilla-luc
control vector (Dual-Luciferase Reporter Assay System,
Promega, Mannheim, Germany) using the method
described above. Expression of the NF-κB luciferase
reporter plasmid was measured using bioluminescence
(Fig. 6B). Basal NF-κB activity in mock-transfected control
cultures was set to a relative standard value (v = 1). Co-
transfection of the NF-κB reporter plasmid and the NF-κB
super-repressor IκB-AA1 significantly decreased the activ-
ity measured. In contrast, TNF treatment increased NF-κB
activity more than 10-fold compared to untreated con-
trols.Page 4 of 18
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p65. Untransfected NSCs were fixed and immunostained
with a p65-antibody (Fig. 6C). This activation-specific
antibody can only react with the nuclear localization sig-
nal (NLS) of p65 when the repressing IκB protein is not
present [27]. TNF treated NSCs showed increased nuclear
TNF-α enhances growth of rat derived neurospheresFigure 2
TNF-α enhances growth of rat derived neurospheres. (A) Photographs of neurospheres, 1 (upper panel) and 4 (lower 
panel) days after plating, show larger neurospheres after TNF treatment than in control neurospheres. Note that 10 ng/ml 
TNF has the greatest size induction effect. Bar, 200 μm. (B) Quantification of neurosphere volume. TNF-treated neurospheres 
show significantly increased volume compared to untreated neurospheres (*** P < 0.0001, **P < 0.05).Page 5 of 18
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BMC Neuroscience 2006, 7:64 http://www.biomedcentral.com/1471-2202/7/64localization of p65 (Fig. 6C, lower panels) compared to
untreated controls (upper panels). Thus, the subcellular
localization of NF-κB correlates with the activation.
TNF treatment elevates expression of cyclin D1 in NSCs
Several reports have shown that the cyclin D family has a
crucial role in cell cycle progression, so we hypothesized
Proliferation of neural stem cells is greatly enhanced by TNF treatmentFigure 3
Proliferation of neural stem cells is greatly enhanced by TNF treatment. (A) Incorporation of bromodeoxyuridin 
(BrdU) into newly-synthesized DNA was determined using BrdU-dependent fluorescence enhancement of TO-PRO-3 (red). 
Cultures (+TNF) were treated with 10 ng/ml TNF for two days. Scale bar depicts 100 μm. Note the larger neurospheres after 
TNF treatment. (B) Quantification of BrdU incorporation is shown as mean ± SEM of at least four independent determinations 
(***P < 0.001). (C) Total cell number determination confirms higher proliferation of TNF-treated cells. Note that pharmaco-
logical blockade of the NF-κB pathway by PDTC counteracts TNF-induced proliferation (***P < 0.001).Page 6 of 18
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κB in NSCs. We analyzed the expression of cyclins D1, D2
and D3 in unsynchronized cells and detected strong
expression of cyclin D1 in some cells (data not shown).
We then synchronized a NSC culture by cold shock (4°C,
24h, see [28] for review). The synchronized cells were
brought back to 37°C for 4 h (cell cycle release) and stim-
ulated with TNF. This treatment strongly activated the
TNF rarely triggers apoptosis in NSCsFigu e 4
TNF rarely triggers apoptosis in NSCs. (A) NSCs were collected using cytospin centrifugation. Apoptosis was detected 
using TUNEL with FITC-conjugated dUTP. Control cultures were treated with DNAse I to generate nicked DNA. Terminal 
deoxynucleotidyl transferase was omitted for negative controls. TNF treatment only slightly increased the number of FITC-
positive cells. (B) Quantification of apoptotic cells (***P < 0.01).Page 7 of 18
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TNF does not interfere with neural stem cell differentiationFigure 5
TNF does not interfere with neural stem cell differentiation. (A) Immunostaining of neuronally differentiated neuro-
sphere-derived NSCs. Cells were cultured on poly-D-lysin/laminin-coated dishes in the absence of EGF and bFGF, as described 
in Materials and Methods. β-III-tubulin expression as a marker for immature neurons was up-regulated in the cells 3 days after 
adhesion to the coated substrate. (B) TNF treatment does not significantly change the percentage of β-III-tubulin positive cells 
(P > 0.05) Bars depict 5 μm. (C) Dissociated NSCs were cultured for four days in the absence of cytokines in medium contain-
ing 10% FCS followed by fixation and staining for GFAP. Note that TNF treatment had no effect on the capacity for differenti-
ation into the glial lineage. Bar, 100 μm.
BMC Neuroscience 2006, 7:64 http://www.biomedcentral.com/1471-2202/7/64
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The effect of TNF on NSCsFigure 6
The effect of TNF on NSCs. (A) TNF activates NF-κB in NSCs as measured by reporter gene activity and nuclear translo-
cation of the p65 subunit. Transfection efficacy was measured with CMV-driven GFP expression plasmids (upper panel). The 
left image depicts a phase contrast image of transfected cells. The middle image shows GFP expression. Both images are 
merged in the right image. Bar depicts 200 μm. Flow cytometry was used to quantify the transfected cells. Control cells 
(untransfected) are shown in white. Transfected cells are shown in grey. Note the high efficacy of transfection (about 60%). (B) 
NSCs were transfected using the optimized conditions shown in (A). Induction of NF-κB by TNF was more than ten-fold. Basal 
κB-dependent reporter gene expression, as measured by bioluminescence under control conditions, was set to 1. (C) TNF-
induced nuclear localization of the transactivating NF-κB subunit p65. Nuclei were stained with SYTOX (green). Activity-spe-
cific anti-p65 immunoreactivity is depicted in red (middle panel). Merged images are shown on the right. Note the basal NF-κB 
activity in unstimulated cells (upper panel). Bar depicts 5 μm. (D) Representative fields of cells were analyzed to determine the 
mean p65 fluorescence in the nucleus. Note that TNF strongly increases nuclear p65 compared to untreated controls. (E) TNF 
treatment elevates cyclin D1 expression in NSCs. Cold-shock synchronized neurospheres were collected on glass slides by 
cytospin centrifugation, fixed and stained for cyclin D1. DNA was stained using SYTOX (green). Note the higher cyclin D1 
expression in TNF-treated cells (lower panels) compared to controls (upper panels). (F) Quantification of cyclin D1 expres-
sion. TNF-treated neurospheres show significantly higher numbers of cyclin D1-positive cells than untreated neurospheres (*** 
P < 0.001). Bars, 20 μm.
BMC Neuroscience 2006, 7:64 http://www.biomedcentral.com/1471-2202/7/64expression of cyclin D1 (Fig. 6E, F). As expected, cyclin D1
was mainly restricted to the NSC nuclei after TNF treat-
ment (note yellow nuclei in lower panel of Fig. 6E). Cyc-
lin D1-positive cells increased more than 4-fold (Fig. 6F)
compared to untreated, synchronized cells. Interestingly,
TNF treatment did not change the expression of cyclins
D2 and D3 (data not shown).
NF-κB regulates neural stem cell proliferation
Next, a functional assay for the role of NF-κB in NSC pro-
liferation was established using transfection with the
transdominant negative super-repressor IκB-AA1. Mock-
transfected, unstimulated cells showed basal NF-κB activ-
ity, which was decreased by the expression of IκB-AA1 (see
Fig. 6B) and resulted in a significantly lower cell number
(Fig. 7). When cells were stimulated with TNF for 2 days,
proliferation was significantly (p < 0.0001) reduced when
the super-repressor IκB-AA1 was transfected (Fig. 7). TNF
treatment caused increased proliferation of control NSCs,
while the division of IκB-AA1 transfected cells was not sig-
nificantly affected (p > 0.05). Taken together, these data
suggest that NF-κB activation might be responsible for
NSC proliferation without the need for additional exoge-
nous TNF (Fig. 7, compare mock-transfected control ver-
sus IκB-transfected cells). These data further demonstrate
that blockade of the NF-κB pathway via transcriptional
repression leads to decreased proliferation of NSCs.
TAK-1 and IKK-β gene knock down decreases endogenous 
and TNF-induced proliferation of NSCs
In view of the well-established role of IKKs in TNF-medi-
ated signaling, we designed a specific siRNA for IKK-β.
Some reports have suggested a potential role for TGFβ-
activated kinase-1 (TAK-1) in the signal cascade under
investigation, suggesting that construction of a siRNA for
this kinase could be informative (Fig 8A and 8B). Gene
knock down of both TAK-1 and IKK-β led to significantly
decreased proliferation in comparison to cells transfected
with control (anti-GFP) siRNA. Interestingly, we observed
that IKK-β knock down affected proliferation more mark-
edly than the silencing of TAK-1 (see Fig 8C). This general
tendency was independent of TNF treatment.
TAK-1 and IKK-β knock down decrease NF-κB activity
We studied the effect of the siRNAs against TAK-1 and
IKK-β on NF-κB activity?. The cells were transiently co-
transfected with siRNA for TAK-1 and κB-luc, or with
siRNA for IKK-β and κB-luc. Endogenous NF-κB activity
was markedly decreased after IKK-β knock down. In con-
trast, the effect of TAK-1 on NF-κB activity was much
weaker (Fig. 8D). TNF treatment led to activation of NF-
κB in siRNA-transfected and un-transfected cells. Never-
theless, IKK-β siRNA-transfected cells showed markedly
decreased NF-κB activity compared to both untransfected
and TAK-1 siRNA transfected cells. Thus, NF-κB activity
correlated with the effect on proliferation after knock
down of TAK-1 and IKK-β (compare Fig. 8C and 8D).
IKK-β but not TAK-1 knock down leads to significantly 
decreased cyclin D1 expression
On the basis of our finding that cyclin D1 was up-regu-
lated after TNF treatment, we investigated the influence of
TAK-1 and IKK-β knock down on cyclin D1 expression in
NSCs. Silencing of IKK-β resulted in strongly decreased
cyclin D1 expression, while TAK-1 knock down induced
only a moderate decrease (Fig. 8E).
IKK-β silencing but not TAK-1 knock down induces 
apoptosis in NSCs
Finally, we investigated the potential induction of apopto-
sis by the siRNAs. NSC apoptosis was enhanced by IKK-β
knock down (see Fig. 8F). TNF treatment had no signifi-
cant effect on the cleavage of caspase-3 and therefore on
the induction of apoptosis in control or TAK-1 siRNA-
transfected cells (Fig. 8F). In contrast, IKK-β siRNA-trans-
fected cells showed a strongly increased apoptosis rate
after TNF treatment (Fig. 8F). Because TNF activated apop-
tosis only moderately in control cells, the up-regulation of
caspase-3 cleavage might be explained by a higher apop-
tosis rate in cells transfected with anti-IKK-β siRNA.
Thus, TAK-1 knock down once again had a weaker biolog-
ical effect than IKK-β silencing. Overall, IKK-β silencing
strongly reduced NF-κB activity and cyclin D1 expression.
In addition, proliferation stopped and apoptosis was
induced, demonstrating that NF-κB has a dual role in
NSCs: survival and proliferation.
Discussion
In this study, we have described a novel mitogenic action
of TNF on adult neural stem cells. We investigated the sig-
naling mechanism involved and showed that prolifera-
tion is crucially dependent on the activation of NF-κB.
Moreover, we showed for the first time that an active
IKKα/β complex and active downstream IκB ubiquitin
ligase are essential for NF-κB activation and the resulting
proliferation of NSCs, as indicated by the pharmacologi-
cal blockade of IκB ubiquitin ligase and gene silencing of
IKK-β via siRNA. In addition, we showed that TNF treat-
ment induces up-regulation of cyclin D1 expression, and
we demonstrated an involvement, but not a crucial role,
of TAK-1 in the signal transduction cascade investigated.
In accordance with our data, TNF was recently identified
as a mitogen in the subventricular zone of rats. Stereotac-
tical injection of TNF-α into the lateral ventricle resulted
in a highly significant increase in proliferating cells 24 h
post-injection [29]. Here we have shown that TNF has a
novel cell-autonomous action on isolated neural stem
cells. This might rule out the potential effects of thePage 10 of 18
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marked up-regulation of TNF expression under patholog-
ical conditions such as infection with Gram negative bac-
teria, Alzheimer's disease, Parkinson's disease and even
brain inflammation [11]. On the other hand, Cacci et al.
reported that TNF is toxic to neural precursor cells when
proliferation has ceased [30]. In contrast, few apoptotic
cells were found in the SVZ of TNF-treated animals [29].
There is much evidence for up-regulation of chemokine
expression and secretion in situations of brain pathology
[11]. Interestingly, most such situations are characterized
by TNF secretion into adjacent tissues. In a previous study
we showed marked up-regulation of MCP-1 expression
and secretion by astroglioma cells after TNF treatment
[10]. Subsequently, we identified MCP-1 as a potent che-
moattractant for NSCs [13]. It is to be expected that in
pathological situations NSCs will migrate from their
endogenous niche (SVZ) in response to chemokines such
as MCP-1, released at the area of inflammation [11]. Thus,
after migration, NSCs are exposed to TNF. In this context,
our results suggest that a major aspect of the physiological
action of TNF on NSCs might be the induction of prolifer-
ation.
Taken together, these data suggest that after CNS injury,
TNF-α not only plays a critical role in the development of
pathology and inflammation, but could also activate NSC
proliferation, which might be a physiological means of
repair and neuroprotection. In accordance with this
hypothesis, Pluchino et al. showed that during CNS
inflammation, NSCs are able to promote neuroprotection
[31]. This phenomenon might be explained by secretion
of neuroprotective cytokines by NSCs.
We used human TNF-α, which has been shown to activate
TNF-RI but not TNF-RII in rat neuronal cultures [32,33].
The cultures used in the present study express both TNF-
RI and TNF-RII. Human TNF-α has been identified as neu-
roprotective in hippocampal neurons [32,34] and cerebel-
lar granule cell precursors [35]. Genetic ablation of TNF-
RI (p55) exacerbates traumatic brain injury and is corre-
lated with reduced NF-κB activation [14]. In contrast,
TNF-α was cytotoxic to mouse-derived neurospheres and
interfered with their formation [36]. These data, which
conflict with those obtained with rat NSCs, might be
attributed either to species differences or the use of
murine TNF, which binds to both TNF receptors. The TNF-
RI receptor is thought to be the major NF-κB activating
TNFR [16].
In a recent study, Mehrhof et al. convincingly showed
genetic evidence for a cell type-restricted requirement for
NF-κB in the control of proliferation [37]. Thus, the role
of NF-κB in proliferation has to be investigated separately
for each cell type. In this study, inhibition of NF-κB
resulted in a pronounced reduction of NSC proliferation.
In the endogenous niche of NSCs – the subventricular
zone and the rostral migratory stream – members of the
NF-κB family are expressed in dividing cells [38]. In addi-
tion, it has been reported that the IKK-α/β-complex is cru-
cial for TNF-mediated NF-κB activation in other systems
[17]. Here we have shown for the first time that IKKs are
crucial for NF-κB activation and NSC proliferation.
There is evidence for the involvement of TGFβ activated
kinase-1 (TAK-1) in the TNF-induced signaling cascade
[18,39]. Here we have shown that TAK-1 is involved in
TNF signaling in NSCs but is not crucial for NF-κB activa-
tion and the resulting proliferation.
Ferguson et al. showed that cyclin dependent kinase 4 and
6 (CDK4/6) signaling is crucial for neural precursor cell
cycle regulation [19]. It is well-established that formation
of a complex between CDKs 4 and 6 and cyclin D1 is nec-
NF-κB activation is responsible for TNF-induced NSC prolif-erationFigure 7
NF-κB activation is responsible for TNF-induced 
NSC proliferation. Note that NF-κB activation is also nec-
essary for the proliferation of NSCs under control condi-
tions (compare mock-transfected control versus IκB 
transfected cells). Transfected cells without IκB expression 
vector were stimulated with TNF. Induction of proliferation 
by TNF is significantly abrogated by IκB co-transfection (***P 
< 0.001).Page 11 of 18
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Gene knock down of TAK-1 and IKK-β impairs TNF-induced stem cell proliferationFigure 8
Gene knock down of TAK-1 and IKK-β impairs TNF-induced stem cell proliferation. (A) NSCs were co-transfected 
with siRNA for GFP and GFP expression vector to monitor the efficacy of the knock down strategy (upper panel). After fixa-
tion, all cells were stained for TAK-1 and IKK-β and counterstained for DNA with DAPI (blue). Note the expression of TAK-
1 (red) and IKK-β in cells transfected with siRNA for GFP (green). In contrast, cells co-transfected with siRNA for TAK-1 (red) 
and GFP expression vector, or with anti IKK-β siRNA and GFP, expressed minimal levels of knocked down proteins (see 
arrowheads). Note that non-transfected, GFP-negative cells showed unaffected TAK-1 expression (marked by arrowhead). 
Bars represent 200 μm. Immunocytochemical results were confirmed by western blotting. Note also the unaffected expression 
of TAK-1 and IKK-β in control (anti GFP siRNA transfected) cells. (B) Western blot analysis of gene knock down. (C) Quanti-
fication of proliferation in siRNA transfected cells. After dissociation of transfected neurospheres, the cell number was deter-
mined as described in Materials and Methods. Note the stronger negative effect of IKK-β knock down compared to TAK-1 
silencing. (D) Reporter gene assay showed down-regulation of NF-κB activity after gene knock down. NF-κB activity was most 
markedly inhibited after IKK-β knock down. (E) Analysis of cyclin D1 expression in cells transfected with siRNAs. Note that 
the most prominent effect was observed in IKK-β siRNA-transfected cells after TNF treatment. (F) Activation of caspase 3 in 
cells transfected with IKK-β and TAK-1 siRNA. Note the strongest effect of IKK-β knock down after TNF stimulation.
BMC Neuroscience 2006, 7:64 http://www.biomedcentral.com/1471-2202/7/64essary for cell cycle progression. Interestingly, Guttridge et
al. demonstrated that NF-κB controls growth and differen-
tiation through transcriptional regulation of cyclin D1
[22]. Here we report for the first time the TNF-mediated
up-regulation of cyclin D1 in NSCs. Cyclin D1 is the
bona-fide NF-κB target gene, with mapped and function-
ally characterized NF-κB binding sites in its promoter
[22,40].
The expression of NF-κB subunits and the induction of
proliferation might suggest that both pathways are linked
in vivo. We have shown for the first time that NF-κB acti-
vation is essential for neural stem cell proliferation. One
might ask if TNF-α can also act as a mitogen in other sys-
tems. In fact, TNF-α is a growth factor for Hodgkin's lym-
phoma, cutaneous T-cell lymphoma and gliomas (see
[41] for discussion). Recent data suggest that NF-κB is
Model for the TNF-dependent activation of proliferation is NSCsFigure 9
Model for the TNF-dependent activation of proliferation is NSCs. The TNF receptor is depicted in purple in the 
plasma membrane. Activation induces phosphorylation of IκB-α via IKKα/β complex at ser 32 and 36, which subsequently leads 
to ubiquitination of IκB by IkB ubiquitin ligase and degradation within the proteasome resulting in nuclear translocation of p50/
p65. Transcription of NF-κB target genes such as cyclin D1 is responsible for proliferation and can be repressed by expression 
of the transdominant negative super-repressor IκB-AA1. In addition, pharmacological blockade of IκB ubiquitin ligase or silenc-
ing of IKK-β via siRNA leads to strongly decreased cyclin D1 expression and proliferation of NSCs. In contrast, TGFβ activated 
kinase-1 (TAK-1) seems to be involved but is not crucial for TNF-mediated NF-κB activation.Page 13 of 18
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hematopoietic or solid tumors [42]. Similarly, we and
others have shown that NF-κB inhibition results in
reduced tumor cell proliferation [21,22](see [43] for
review).
Indeed, the requirement for activated NF-κB is not the
only similarity between dividing tumor cells and stem
cells. Recent evidence suggests that formation of tumors
might be restricted to cells with stem cell markers [44].
Our data might be especially relevant to brain tumors
such as glioblastomas that contain cancer stem cells [45].
Only a few cells are endowed with the ability to replicate
and thus to transfer the tumor phenotype residing within
medulloblastomas and astrocytomas. These cancer stem
cells derived from brain tumors formed NSCs and were
positive for the neural stem cells markers Nestin and
CD133 [45].
Understanding the mechanisms that regulate stem cell
proliferation might be crucial for future regenerative and
anti-tumor medicine.
Conclusion
This study provides experimental evidence that NF-κB is a
crucial regulator of NSC proliferation. In addition to pro-
viding novel insights in the mechanisms governing adult
stem cell self-renewal, this study might add a cautionary
note about the use of anti-cell-proliferative agents in
tumor therapy.
Methods
Isolation and culture of adult neural stem cells (NSCs)
Adult rats were killed by decapitation. NSCs were isolated
from the lateral subventricular zone using visually guided
micro-preparation under a dissection microscope (Zeiss,
Jena, Germany, magnification 8x [2]). About 3 mm of
subventricular tissue was prepared with fresh scalpel
blades, isolated with Dumont forceps and collected in ice-
cold HBSS (Gibco, Eggenstein, Germany) containing 300
mg/ml D-glucose (Sigma, Deisenhofen, Germany). Cells
from adjacent tissue not containing stem cells generally
do not proliferate in growth-promoting medium. Isolated
tissue was digested at 37°C with 1.33 mg/ml trypsin
(Sigma, Deisenhofen, Germany), 0.7 mg/ml hyaluroni-
dase (Sigma, Deisenhofen, Germany), 200 U/ml DNAse
(Sigma, Deisenhofen, Germany) and 0.2 mg/ml
kynurenic acid (Sigma, Deisenhofen, Germany) to disso-
ciate cells. The tissue was passed through a 70 μm cell
strainer (BD Falcon; Heidelberg, Germany) and trans-
ferred to ice-cold, serum-free medium containing BSA
(Sigma, Deisenhofen, Germany) to stop trypsin activity.
NSCs were cultured in serum-free medium containing
basic fibroblast growth factor (bFGF; 10 ng/ml, Chemi-
con, Hofheim, Germany), epidermal growth factor (EGF;
20 ng/ml; R&D Systems, Wiesbaden, Germany) and B27
supplement (Gibco, Eggenstein, Germany). Primary neu-
rospheres were dissociated at day 8–10 using Accutase
(PAA, Pasching, Austria) to derive clonal neurospheres.
The sub-culturing protocol consisted of neurosphere pas-
saging every 3–4 days with whole culture medium change
(fresh growth factors were added).
Immunocytochemistry
Neurospheres were harvested on microscope slides by cyt-
ospin centrifugation (212 g, 5 min., Shandon, Thermo,
Dreieich, Germany), fixed in 3.7% PFA for 60 min at 4°C
and washed 3x in 1x PBS for 5 min. Blocking was per-
formed in 5% appropriate serum for 30 min followed by
incubation with anti-Nestin (1:100, BD Pharmingen, Hei-
delberg, Germany); anti-GFAP (BD Pharmingen, Heidel-
berg, Germany, 1:100), anti-β-III-tubulin (Promega,
Mannheim, Germany, 1:50), anti-TNF-RI (abcam, Cam-
bridge, UK, 1:100), anti-TNF-RII (Alexis Biochemicals,
Grünberg, Germany), anti-LeX (Developmental Hybrid-
oma Bank, Iowa City, USA, 1:100), anti Sox2 (Sigma,
Deisenhofen, Germany, 1:100), anti-Musashi (Chemi-
con, 1:100), anti-L1 (Developmental Hybridoma Bank,
Iowa City, USA, 1:100), anti-PSA-NCAM (Miltenyi Biotec,
Bergisch Gladbach, Germany), anti-Notch1 (Develop-
mental Hybridoma Bank, Iowa City, USA, 1:100), anti-
Notch2 (Santa Cruz, 1:50), anti-A2B5 (Chemicon,
1:100), and anti DCX (Santa Cruz, 1:50), anti-TAK-1
(Santa Cruz, 1:50), anti IKK-β (Biosource, 1:50) and anti-
cleaved caspase 3 (Cell Signaling Technology, Danvers,
USA). Positive antibody binding was detected using a
Cy3-conjugated antibody (1:300, Jackson Immuno
Research Laboratories, distributed by Dianova, Hamburg,
Germany). Nuclei were stained with SYTOX (1:10000,
Molecular Probes, Göttingen, Germany). Staining was vis-
ualized using confocal laser scanning microscopy (LSM
Pascal, Zeiss, Jena, Germany).
Reverse transcription polymerase chain reaction
Total RNA was isolated (RNAeasy, Qiagen, Hilden, Ger-
many) from adult neurospheres according to the manu-
facturer's instruction and reverse transcribed. To exclude
DNA contamination, mRNA was treated with DNAse
(Qiagen). The PCR primers (Qiagen) were: 5'-
ATGGGTCTCCCCATCGTGCCTG, 3'- TTATCGCGGGAG-
GTGGGTCGTG for TNF-RI and 5'- CACACAGT-
GCCCGCCAAGGTTGT, 3'-
TCAAGGCACTTTGACAGCAATCTGGTC for TNF-RII.
Analysis of neurosphere growth
Secondary neurospheres were harvested, dissociated using
Accutase (PAA, Pasching, Austria) and passed through a
40 μm cell strainer (BD Falcon, Heidelberg) to obtain a
single neural stem cell suspension. Cells were cultured in
serum-free medium containing basic fibroblast growthPage 14 of 18
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epidermal growth factor (EGF; 20 ng/ml; R&D Systems,
Wiesbaden, Germany) and B27 supplement (Gibco, Egg-
enstein, Germany) and 10 ng/ml TNF (Calbiochem,
Schwalbach, Germany). Control cells were cultured in
neurosphere medium without TNF. The volume of living
neurospheres was measured using an inverse microscope
(Axiovert 100, Carl Zeiss, Jena, Germany) and ImageJ soft-
ware (National Institute of Health, USA; [46]). Statistical
significance was determined by ANOVA with Bonferroni
correction, using GraphPad's Prism. P ≤ 0.05 was consid-
ered significant.
BrdU incorporation assay
BrdU assays were performed as described [47]. Briefly, 10
μM bromodeoxyuridin (BrdU, Sigma, Deisenhofen, Ger-
many) was added to neurosphere cultures each day. Sev-
enty-two hours after TNF stimulation (10 ng/ml), the
neurospheres were harvested on microscope slides by Cyt-
ospin centrifugation (212 g, 5 min., Shandon, Thermo,
Dreieich, Germany). The cells were fixed with 3.7% PFA
for 60 min at 4°C and counterstained with 0.3 μM ToPro-
3-iodite (Molecular Probes, Göttingen, Germany). Incor-
poration of BrdU into newly-synthesized DNA in the
NSCs was detected by BrdU-dependent fluorescence
enhancement of ToPro-3-iodite. Fluorescence was moni-
toring using an inverse confocal laser scanning micro-
scope (LSM 5, Pascal, Carl Zeiss, Jena, Germany). Relative
cell proliferation was calculated from the fluorescence of
5 fields of view (n = 4 for each condition) as follows: rel-
ative percentage of cell proliferatio = (Fexp - Fmin)/(Fmax -
Fmin) × 100. Fexp is the fluorescence of the experimental
test condition, Fmax is the maximal fluorescence and Fmin
is the background fluorescence. Differences in relative cell
proliferation were assessed by two-way ANOVA followed
by a post-hoc t-test with Bonferroni correction. Differ-
ences between two conditions at P ≤ 0.05 were considered
statistically significant.
Apoptosis assay
Neurospheres were prepared, cultured and collected as
described above, with either 10 ng/ml TNF or neuro-
sphere medium alone. After fixation, an In Situ Cell Death
Detection Kit FITC (Roche, Mannheim, Germany) was
used for immunocytochemical detection of apoptosis,
based on labeling of DNA strand breaks (TUNEL technol-
ogy) according to the manufacturer's instructions. Fluo-
rescein isothiocyanate (FITC) fluorescence was monitored
using an inverse confocal laser scanning microscope (LSM
5, Pascal, Carl Zeiss, Jena, Germany). As positive control,
neurospheres were treated with DNAse (2000 U/ml,
Sigma, Deisenhofen, Germany). As negative control, labe-
ling solution containing FITC was used. The relative per-
centage of apoptotic cells was calculated from the
fluorescence of 4 fields of view (n = 4 for each condition,
relative percentage of apoptotic cells = (Fexp - Fmin)/(Fmax -
Fmin) × 100; key as above). Statistical significance was
determined by ANOVA. P ≤ 0.05 was considered signifi-
cant.
Determination of cell number
Neural stem cells were plated at 1.0 × 106 cells/ml in trip-
licate for each condition. For pharmacological blockade
of the NF-κB pathway, neural stem cells were pre-treated
for 30 min with 0.1 mM pyrrolidine dithiocarbamate
(PDTC, Sigma, Deisenhofen, Germany). TNF-α was
added to the cultures at plating. Spheres were collected at
6, 24, 48 and 72 h after plating and dissociated, and total
cell numbers were counted. Results were expressed as the
mean ± SEM. Statistical significance was determined using
two-way ANOVA followed by a post-hoc t-test with Bon-
ferroni correction. Differences between two conditions at
P = 0.05 were considered statistically significant.
Neuronal differentiation of TNF-treated neurosphere-
derived cells
Secondary neurospheres were harvested and dissociated
as described above. NSCs were cultured in serum-free
medium containing B27 supplement and TNF but with-
out EGF and bFGF or in medium without TNF addition
and plated on poly-D-lysine/laminin-coated culture slides
(BD Biocoat, Heidelberg, Germany). Three days after the
TNF stimulus the cells were fixed, stained and analyzed as
described above.
Glial differentiation
Secondary neurospheres were harvested and dissociated,
followed by culture in DMEM/F:12 (Gibco) and 10% FBS
(PAA, Pasching, Austria). After 4 days of culture the cells
were fixed, stained and analyzed as described above.
Reporter gene assay (transfection and analysis)
Neurospheres were dissociated as described above and
transfected using a Rat NSC Nucleofector Kit (Amaxa,
Köln, Germany) according to the manufacturer's instruc-
tions with minor modifications. In particular, 5.0 × 106
cells were used for each transfection. After dissociation of
the neurospheres (see above), cells were centrifuged at
210 × g for 10 min and re-suspended in an appropriate
volume of Amaxa Nucleofector solution. After addition of
DNA, the cells were electroporated in an Amaxa device
and collected in 10 ml preheated cytokine-free media.
After further centrifugation at 210 × g (10min), the cells
were re-suspended at appropriate density in cytokine-con-
taining medium. Transfection efficiency was measured
using the pmaxGFP vector (Amaxa) and analysis by fluo-
rescence microscopy (Axiovert 100, Carl Zeiss, Jena) and
flow cytometry (FACScalibur, Becton Dickinson, Heidel-
berg, Germany).Page 15 of 18
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ulated neural stem cells, a Dual-Luciferase Reporter Assay
System (Promega, Mannheim, Germany) and κB-luc
Reporter (BD Clonetech, Heidelberg, Germany) was used.
All cells were transfected with κB-luc reporter vector and
Renilla-luc control vector (Promega, Mannheim, Ger-
many). IκB-AA1 (super-repressor of NF-κB, cloned into
the commercially available Rc/CMV expression vector
(Promega) [48]) was cotransfected. As a mock vector,
pMETalpha (Invitrogen) without insert was used. Forty-
eight hours after transfection, the cells were lysed and
assayed for promoter-dependent luciferase activity versus
promoter independent Renilla-luc activity (Lumat
LB9507 device, Berthold Technologies, Bad Wildbach,
Germany). A representative experiment is shown.
Detection of nuclear NF-κB in TNF-stimulated neural stem 
cells
Neurospheres were stimulated with 10 ng/ml TNF. Thirty
minutes after the TNF stimulus, the cells were harvested
and fixed as described above. After 30 min permeabiliza-
tion with 0.5% TritonX100/PBS and blocking with 5%
goat serum, the cells were stained with anti-p65 antibody
(Chemicon, Hofheim, Germany, 1:50). Nuclear NF-κB
was detected with Cy3-conjugated anti-mouse antibody
(1:300, Jackson Immuno Research Laboratories, distrib-
uted by Dianova, Hamburg, Germany). Nuclei were
stained with SYTOX (1:10000, Molecular Probes, Göttin-
gen, Germany). Antibody staining was visualized using
confocal laser scanning microscopy (LSM Pascal, Zeiss,
Jena, Germany). Laser power and detector settings were
kept constant to maintain consistency in the data collec-
tion system. Fluorescence intensity was quantified using
Image J image analysis software [46]. Statistical signifi-
cance was determined by ANOVA with Bonferroni correc-
tion, using GraphPad's Prism. P < 0.05 was considered
significant.
Detection of TNF-induced cyclin expression
Neural stem cells were dissociated, cultured for 24 h as
described above and synchronized by cold shock (24 h,
4°C). After 4 h equilibration at 37°C (release into cell
cycle), 10 ng/ml TNF-α was added.
Four hours after TNF stimulation, neurospheres were har-
vested on microscope slides by Cytospin centrifugation
(212 g, 5 min, Shandon, Thermo, Dreieich, Germany),
fixed in 3.7% PFA for 60 min at 4°C and washed 3x in 1x
PBS for 5 min followed by permeabilization with 0.1%
Triton X-100 for 30 min. Blocking was done in 5% appro-
priate serum for 30 min followed by incubation with anti-
cyclin D1 (Sigma, Deisenhofen, Germany, 1:100), anti-
cyclin D2 (abcam, Cambridge, UK 1:100) and anti-cyclin
D3 (Sigma, Deisenhofen, Germany, 1:100). Antibody
binding was detected with Cy3-conjugated antibody
(1:300, Jackson Immuno Research Laboratories, distrib-
uted by Dianova, Hamburg, Germany). Nuclei were
stained with SYTOX (1:10000, Molecular Probes, Göttin-
gen, Germany). Antibody staining was visualized using
confocal laser scanning microscopy (LSM Pascal, Zeiss,
Jena, Germany).
Gene silencing (siRNA design and transfection)
The Ambion Silencer siRNA Construction Kit (Ambion)
was used to produce siRNAs against TAK-1 and IKK-β. The
target sequences were identified and appropriate oligonu-
cleotides constructed as per the manufacturer's instruc-
tions. The target sequences for TAK-1 and IKK-β knock
down were identified, followed by Blast searches to ensure
that the sequences did not contain significant homology
to any other known genes. The sequences were TGGCT-
TATCTTACACTGGA for TAK-1 and GGTGGAAGAGGT-
GGTGAGC for IKK-β. Both produced similar levels of
specific gene product knockdown. In addition, siRNA for
GFP (Amaxa, Köln, Germany) was used as a control.
Cells were transiently co-transfected as described above,
either with siRNA for the TAK-1 and CMV driven GFP or
with siRNA for IKK-β and CMV-GFP, to monitor the effi-
cacy of transfection. All cells were counterstained with
DAPI. As control, anti-GFP siRNA and CMV-GFP were
transfected. After 48 h, the down-regulation of TAK-1 and
IKK-β was analyzed using fluorescence microscopy (Axio-
vert, Zeiss, Jena, Germany) and western blots.
Western blot analysis
Soluble cell protein (250 μg per condition) was separated
by SDS-PAGE using 8% polyacrylamide gels and electrob-
lotted on to PVDF membranes (Millipore Corporation,
Bedford, MA, USA). The membranes were blocked in
TBST+3% nonfat dry milk. The following first antibodies
were used: mouse monoclonal anti-IKK-β (Biosource)
and goat polyclonal anti-TAK-1 (Santa Cruz Biotechnol-
ogy). For detection, horseradish peroxidase-conjugated
goat anti-mouse (Bio-Rad Laboratories GmbH,
Muenchen, Germany) and donkey anti-goat (Santa Cruz
Biotechnology) IgGs were used with an ECL kit (Amer-
sham Pharmacia Biotech) according to the manufacturer's
protocol.
Influence of gene silencing on proliferation, NF-κB activity, 
cyclin D1 expression and apoptosis
Anti TAK-1 and anti IKK-β siRNA transfected adult neural
stem cells were cultivated for 24 h. Cells were then stimu-
lated with 10 ng/ml TNF and cultivated for up to 48 h. The
total cell number was determined as described above.
To investigate NF-κB activity, the cells were co-transfected
with siRNA for TAK-1 and κB-luc reporter vector or siRNA
for IKK-β and κB-luc. Twenty-four hours after transfec-Page 16 of 18
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tivated for an additional 24 h, then lysed and assayed for
promoter-dependent luciferase activity as described
above. To study the influence of gene product knock
down on cyclin D1 expression and apoptosis, the cells
were transfected with siRNAs for TAK-1 and IKK-β fol-
lowed by 24 h cultivation. Cells were then stimulated with
TNF, cultured for an additional 24 h, stained for cyclin D1
and cleaved caspase3 (Cell Signaling Technologies, Dan-
vers, USA, 1:100) and counterstained with DAPI. GFP-
positive cells were analyzed for TAK-1 and IKK-β immu-
noreactivity.
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